Please assess the completion status of the following clinical trial:

Trial Title: Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants legally competent to sign and give informed consent and, if appropriate, assent as required by local laws.~* Males and females ages 9 years and older at the time of consent.~* Clinical diagnosis of seborrheic dermatitis of at least 3 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks.~* Seborrheic dermatitis up to 20% BSA involvement. Involvement may be of the scalp and/or face and/or trunk and/or intertriginous areas.~* An Investigator Global Assessment (IGA) disease severity of at least Moderate ('3') at Baseline.~* Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline.~* Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).~* Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.~* Subjects in good health as judged by the Investigator.~* Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.~Key Exclusion Criteria:~* Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study.~* Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.~* Previous treatment with ARQ-154 or ARQ-151.~* Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.~* Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.~* Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.~* Subjects, parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s).~* Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members living in the same house of enrolled subjects.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast Foam 0.3% (Type: EXPERIMENTAL): Participants with seborrheic dermatitis apply roflumilast foam 0.3% once daily (QD) for 8 weeks.
- Vehicle Foam (Type: PLACEBO_COMPARATOR): Participants with seborrheic dermatitis apply vehicle foam QD for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).